L. Torre, F. Bray, R. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, 2012, Global cancer statistics, pp.87-108, 2012.
DOI : 10.1038/nrc1948

J. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-rubio et al., Openlabel , uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity Fig. 5. Correlation between mRNA levels of Tim-3 (x-axis) and PD-1, CTLA-4, LAG-3, and TGF? (y-axis) in expanded TILs, Linear trend lines and regression coefficients are shown

K. Hladíková, Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1, Oral Oncology, vol.82, pp.75-82, 2018.
DOI : 10.1016/j.oraloncology.2018.05.010

, of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy, J Clin Oncol, vol.25, pp.2171-2178, 2007.

T. Seiwert, B. Burtness, R. Mehra, J. Weiss, R. Berger et al., Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, The Lancet Oncology, vol.17, issue.7, pp.956-65, 2016.
DOI : 10.1016/S1470-2045(16)30066-3

J. Bauml, T. Seiwert, D. Pfister, F. Worden, S. Liu et al., Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study, Journal of Clinical Oncology, vol.35, issue.14, pp.1542-1551, 2017.
DOI : 10.1200/JCO.2016.70.1524

R. Ferris, B. G. Jr, F. J. Guigay, J. Colevas, A. Licitra et al., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.375, issue.19, pp.1856-67, 2016.
DOI : 10.1056/NEJMoa1602252

J. Fourcade, Z. Sun, M. Benallaoua, P. Guillaume, I. Luescher et al., T cell dysfunction in melanoma patients, The Journal of Experimental Medicine, vol.18, issue.10, pp.2175-86, 2010.
DOI : 10.1038/ni1271

S. Koyama, E. Akbay, Y. Li, G. Herter-sprie, K. Buczkowski et al., Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nature Communications, vol.43, p.10501, 2016.
DOI : 10.1093/nar/gkv007

S. Best, K. Niparko, and S. Pai, Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers, Otolaryngologic Clinics of North America, vol.45, issue.4, pp.807-829, 2012.
DOI : 10.1016/j.otc.2012.04.005

C. Badoual, S. Hans, N. Merillon, C. Van-ryswick, P. Ravel et al., PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer, Cancer Research, vol.73, issue.1, pp.128-166, 2013.
DOI : 10.1158/0008-5472.CAN-12-2606

S. Best, S. Peng, C. Juang, C. Hung, D. Hannaman et al., Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery, Vaccine, vol.27, issue.40, pp.5450-5459, 2009.
DOI : 10.1016/j.vaccine.2009.07.005

R. Macedo, J. Rochefort, M. Guillot-delost, K. Tanaka, L. Moignic et al., Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles, OncoImmunology, vol.56, issue.7, p.1164363, 2016.
DOI : 10.1158/0008-5472.CAN-12-2606

G. Kenter, M. Welters, A. Valentijn, M. Lowik, D. Berends-van-der-meer et al., Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia, New England Journal of Medicine, vol.361, issue.19, pp.1838-1885, 2009.
DOI : 10.1056/NEJMoa0810097

A. Albers, K. Abe, J. Hunt, J. Wang, A. Lopez-albaitero et al., Antitumor Activity of Human Papillomavirus Type 16 E7???Specific T Cells against Virally Infected Squamous Cell Carcinoma of the Head and Neck, Cancer Research, vol.65, issue.23, pp.11146-55, 2005.
DOI : 10.1158/0008-5472.CAN-05-0772

M. Heusinkveld, R. Goedemans, R. Briet, H. Gelderblom, J. Nortier et al., Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer, International Journal of Cancer, vol.358, issue.2, pp.74-85, 2012.
DOI : 10.1056/NEJMoa072685

URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.26497/pdf

M. Heusinkveld, M. Welters, M. Van-poelgeest, J. Van-der-hulst, C. Melief et al., The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors, International Journal of Cancer, vol.104, issue.2, pp.379-89, 2011.
DOI : 10.1111/j.1048-891X.2004.014211.x

T. Hoffmann, C. Arsov, K. Schirlau, M. Bas, U. Friebe-hoffmann et al., T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx, International Journal of Cancer, vol.62, issue.8, pp.1984-91, 2006.
DOI : 10.1046/j.1365-2567.2002.01442.x

S. Partlova, J. Boucek, K. Kloudova, E. Lukesova, M. Zabrodsky et al., Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma GP5+/6+ PCR followed by reverse line blot analysis enables rapid and highthroughput identification of human papillomavirus genotypes, Oncoimmunology J Clin Microbiol, vol.440, pp.779-87, 2002.

C. Lajer and C. Von-buchwald, The role of human papillomavirus in head and neck cancer, APMIS, vol.49, issue.3 Pt 1, pp.510-519, 2010.
DOI : 10.1177/000348940911801010

W. Spanos, P. Nowicki, D. Lee, A. Hoover, B. Hostager et al., Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus???Related Head and Neck Cancer, Archives of Otolaryngology???Head & Neck Surgery, vol.135, issue.11, pp.1137-1183, 2009.
DOI : 10.1001/archoto.2009.159

URL : http://archotol.jamanetwork.com/data/journals/otol/9846/ooa90089_1137_1146.pdf

S. Daayana, E. Elkord, U. Winters, M. Pawlita, R. Roden et al., Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia, British Journal of Cancer, vol.43, issue.7, pp.1129-1165, 2010.
DOI : 10.1158/1078-0432.CCR-05-1244

URL : http://www.nature.com/bjc/journal/v102/n7/pdf/6605611a.pdf

E. Wherry, T cell exhaustion, Nature Immunology, vol.460, issue.6, pp.492-501, 2011.
DOI : 10.4049/jimmunol.0901297

T. Inozume, K. Hanada, Q. Wang, M. Ahmadzadeh, J. Wunderlich et al., Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells, Journal of Immunotherapy, vol.33, issue.9, pp.956-64, 2010.
DOI : 10.1097/CJI.0b013e3181fad2b0

I. Verbrugge, J. Hagekyriakou, L. Sharp, M. Galli, A. West et al., Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies, Cancer Research, vol.72, issue.13, pp.3163-74, 2012.
DOI : 10.1158/0008-5472.CAN-12-0210

URL : http://cancerres.aacrjournals.org/content/canres/72/13/3163.full.pdf

C. Granier, C. Dariane, P. Combe, V. Verkarre, S. Urien et al., T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma, Cancer Research, vol.77, issue.5, pp.1075-82, 2017.
DOI : 10.1158/0008-5472.CAN-16-0274

K. Sakuishi, L. Apetoh, J. Sullivan, B. Blazar, V. Kuchroo et al., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, The Journal of Experimental Medicine, vol.207, issue.10, pp.2187-94, 2010.
DOI : 10.1038/nri1936

URL : http://jem.rupress.org/content/jem/208/6/1331.full.pdf

G. Shayan, R. Srivastava, J. Li, N. Schmitt, L. Kane et al., Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer, OncoImmunology, vol.6, issue.1, p.1261779, 2017.
DOI : 10.4049/jimmunol.1102609

URL : http://europepmc.org/articles/pmc5283618?pdf=render

M. Buck, R. Sowell, S. Kaech, and E. Pearce, Metabolic Instruction of Immunity, Cell, vol.169, issue.4, pp.570-86, 2017.
DOI : 10.1016/j.cell.2017.04.004

URL : http://europepmc.org/articles/pmc5648021?pdf=render

D. Bommarito, C. Hall, L. Taams, and V. Corrigall, Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1, Clinical & Experimental Immunology, vol.43, issue.3, pp.455-66, 2017.
DOI : 10.1111/1346-8138.13339

URL : http://onlinelibrary.wiley.com/doi/10.1111/cei.12949/pdf

A. Kinter, E. Godbout, J. Mcnally, I. Sereti, G. Roby et al., The Common ??-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands, The Journal of Immunology, vol.181, issue.10, pp.6738-6784, 2008.
DOI : 10.4049/jimmunol.181.10.6738

J. Matsuzaki, S. Gnjatic, P. Mhawech-fauceglia, A. Beck, A. Miller et al., T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proceedings of the National Academy of Sciences, vol.107, issue.17, pp.7875-80, 2010.
DOI : 10.1038/ni.1679

URL : http://www.pnas.org/content/107/17/7875.full.pdf

K. Hladíková, Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1, Oral Oncology, vol.82, pp.75-82, 2018.
DOI : 10.1016/j.oraloncology.2018.05.010